{"schema_version":"secwatch.filing_event.v1","accession":"0001023024-23-000016","form_type":"8-K","ticker":"ANIP","cik":"0001023024","company_name":"ANI PHARMACEUTICALS INC","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.910268+00:00","generated_at":"2026-06-11T21:09:55.005548+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"ANI Pharma Q2 revenue $116.5M (+57.8% YoY); raises FY2023 guidance","bullets":["Record Q2 net revenues of $116.5M (up 57.8% YoY); GAAP diluted EPS $0.29 vs $(0.94) loss in Q2 2022.","Adjusted non-GAAP EBITDA $34.1M (up 246% YoY); adjusted diluted EPS $1.28 vs $0.13.","Cortrophin Gel net sales $24.3M (+138.2% YoY); record new patient starts and prescribers.","Raised FY2023 guidance: net revenue $425M-$445M (from $385M-$410M); adj. EBITDA $115M-$125M.","Ended Q2 with $161.7M cash; completed equity offering with $80.6M net proceeds."],"urls":{"canonical":"https://secwatch.observer/filing/0001023024-23-000016","json":"https://secwatch.observer/filing/0001023024-23-000016.json","markdown":"https://secwatch.observer/filing/0001023024-23-000016.md","text":"https://secwatch.observer/filing/0001023024-23-000016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1023024/000102302423000016/0001023024-23-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1023024/000102302423000016/ani-20230809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T21:09:55.005548+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"77580c1637605fa3bc15aa5f9c2d992b21c8e3f2","claim":"ANI PHARMACEUTICALS INC reported Q2 2023 results: revenue $116.5 million, net income $5.8 million, EPS $0.29. Guidance raised.","evidence_excerpt":"Pharmaceuticals Reports Record Second Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance Second Quarter 2023 Financial Results -- Record quarterly net revenues of $116.5 million, representing year-over-year growth of 57.8%; net income available to common shareholders of $5.8 million and diluted GAAP income per share of $0.29 -- -- Record quarterly","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1023024/000102302423000016/0001023024-23-000016-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Q2 2023"},{"label":"Revenue","value":"$116.5 million"},{"label":"Net income","value":"$5.8 million"},{"label":"EPS","value":"$0.29"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}